Twitter feed
Follow us
Roche's Tecentriq in combination with Abraxane approved for metastatic triple-negative breast cancer in Europe. - https://t.co/jkxfNRM4AE
Italy’s drug pricing reform in trouble as Prime Minister Conte resigns - https://t.co/qFvY61q6MX
US Government is considering introduction of International Reference Pricing - https://t.co/ZGDCwNGclb
Canada finalises new regulations to tackle high drug prices - https://t.co/PpGxECtT3Y
The new Pricing System in Russia will lead to price decreases for many medicines - https://t.co/uOTiv4G5qT
Renting a lifetime therapy vs. Buying a ‘one-off’ – Has the high price tag historically hindered reimbursement? - https://t.co/fn1yw4QwPb
Analytics and Forecasting for efficient business development, early pricing and target product profile optimisation. - https://t.co/JaMsARTqkd
Prices of Pfizer's leukaemia drug Bosulif cut by 13% in Germany after HTA - https://t.co/Dmwal4RyuX
New set of rules regulating medicine prices in Kazakhstan - https://t.co/6TMLmw7etl
Malaysian authorities approve the introduction of IRP - https://t.co/aZNjtkvNbc
New IRP rule introduced in Greece - https://t.co/R4DxeKoZO7
Harmonisation of HTA practice: Underlying methodological differences across HTA agencies that impact national list prices - https://t.co/Tczhkp1sUs
Employee Spotlight - Shivani Shah - https://t.co/dxTC8mOewV
Employee Spotlight - Madhuri Chhatbar - https://t.co/wQvdpCkKPt
Employee Spotlight - Pramod Mali - https://t.co/hDVRbXzpIz
Pricing pharmaceuticals: The transition from prospective qualitative research to predictive data analytics - https://t.co/UIRe7jJgXn
Employee Spotlight - Popat Bankar - https://t.co/RvAMPV93XV
Employee Spotlight - Tom Brockbank - https://t.co/RKKFjmzqfi
Employee Spotlight - https://t.co/UQRHlPqHK7
GPI are Hiring! - https://t.co/N4juMSDQrS
Combination therapy for melanoma: What are the current challenges in pricing & access from EU and US payers’ perspective? https://t.co/W8dHEA1tNu
Taking stock: European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations via @PricingGlobal
Taking stock: European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations
Fertile ground for cross-border cooperation Even with pan-European EMA approval, pricing is still a country-level issue, with national governments, re...
globalpricinginnovations.wordpress.com
Taking stock: European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations https://t.co/Ar1IA9H3ss
Learn – Engage – Apply – Perform! GPI has launched LEAP; our new career development & training programme https://t.co/zn3nhxrvHU
Pricing policy: Germany – a court ruling as soon as June could set a new tone for AMNOG pricing… but is access becoming a more complex moving target for industry? https://t.co/6WoHxLdRVR
Need a new approach to your pricing strategies? Watch GPI’s video to learn more about our innovative methodologies…
Need a new approach to your pricing strategies? Watch GPI’s video to learn more about our innovative methodologies…
Video post by @PricingGlobal.
globalpricinginnovations.wordpress.com
Thanks for a great Day 1. The GPI team looks forward to doing it all again today! #PPMA @globalpricing
The GPI team looks forward to meeting all delegates at PPMA in London next week (# Stand 31). We are running a short GPI PPMA Challenge Quiz for congress delegates. Go on to the PPMA EU 2018 Congress App for details. #PPMA
What will shape the global pharmaceutical pricing environment in 2018? https://t.co/9vyE96EBgI
Spark's planned price for Luxturna gene therapy for rare blindness too high: ICER
Roche's Tecentriq in combination with Abraxane approved for metastatic triple-negative breast cancer in Europe. - https://t.co/jkxfNRM4AE
Italy’s drug pricing reform in trouble as Prime Minister Conte resigns - https://t.co/qFvY61q6MX
US Government is considering introduction of International Reference Pricing - https://t.co/ZGDCwNGclb
Canada finalises new regulations to tackle high drug prices - https://t.co/PpGxECtT3Y
The new Pricing System in Russia will lead to price decreases for many medicines - https://t.co/uOTiv4G5qT
Renting a lifetime therapy vs. Buying a ‘one-off’ – Has the high price tag historically hindered reimbursement? - https://t.co/fn1yw4QwPb
Analytics and Forecasting for efficient business development, early pricing and target product profile optimisation. - https://t.co/JaMsARTqkd
Prices of Pfizer's leukaemia drug Bosulif cut by 13% in Germany after HTA - https://t.co/Dmwal4RyuX
New set of rules regulating medicine prices in Kazakhstan - https://t.co/6TMLmw7etl
Malaysian authorities approve the introduction of IRP - https://t.co/aZNjtkvNbc
New IRP rule introduced in Greece - https://t.co/R4DxeKoZO7
Harmonisation of HTA practice: Underlying methodological differences across HTA agencies that impact national list prices - https://t.co/Tczhkp1sUs
Employee Spotlight - Shivani Shah - https://t.co/dxTC8mOewV
Employee Spotlight - Madhuri Chhatbar - https://t.co/wQvdpCkKPt
Employee Spotlight - Pramod Mali - https://t.co/hDVRbXzpIz
Pricing pharmaceuticals: The transition from prospective qualitative research to predictive data analytics - https://t.co/UIRe7jJgXn
Employee Spotlight - Popat Bankar - https://t.co/RvAMPV93XV
Employee Spotlight - Tom Brockbank - https://t.co/RKKFjmzqfi
Employee Spotlight - https://t.co/UQRHlPqHK7
GPI are Hiring! - https://t.co/N4juMSDQrS
Combination therapy for melanoma: What are the current challenges in pricing & access from EU and US payers’ perspective? https://t.co/W8dHEA1tNu
Taking stock: European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations via @PricingGlobal
Taking stock: European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations
Fertile ground for cross-border cooperation Even with pan-European EMA approval, pricing is still a country-level issue, with national governments, re...
globalpricinginnovations.wordpress.com
Taking stock: European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations https://t.co/Ar1IA9H3ss
Learn – Engage – Apply – Perform! GPI has launched LEAP; our new career development & training programme https://t.co/zn3nhxrvHU
Pricing policy: Germany – a court ruling as soon as June could set a new tone for AMNOG pricing… but is access becoming a more complex moving target for industry? https://t.co/6WoHxLdRVR
Need a new approach to your pricing strategies? Watch GPI’s video to learn more about our innovative methodologies…
Need a new approach to your pricing strategies? Watch GPI’s video to learn more about our innovative methodologies…
Video post by @PricingGlobal.
globalpricinginnovations.wordpress.com
Thanks for a great Day 1. The GPI team looks forward to doing it all again today! #PPMA @globalpricing
The GPI team looks forward to meeting all delegates at PPMA in London next week (# Stand 31). We are running a short GPI PPMA Challenge Quiz for congress delegates. Go on to the PPMA EU 2018 Congress App for details. #PPMA
What will shape the global pharmaceutical pricing environment in 2018? https://t.co/9vyE96EBgI
Spark's planned price for Luxturna gene therapy for rare blindness too high: ICER
